Down 3 to 5 bucks a share. It is quite common for the panel to recomend approval , but in this situation, it is clear that safety is a huge concern here. The FDA simply can not approive a drug and subsequently request a company to tudy for a lower dose. The longs get off the hook this time, but will be disappointed within the next 10 days.
Probably will trade between 25 and 30 (near it's recent peak) and will move higher in the upcoming days. Will again shoot up after the official FDA approval on Oct 23rd. Probably will settle around 40 unless acquired by Biogen or another Pharmaceutical interested in it's prospective pipeline drugs. The stock deserves to be around 50 within a 1 year time frame.